XORTX Therapeutics, Inc.(Canadian National Stock Exchange : XRTX)
XRTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||1.96%||81.05||0.7%||$1593.78m|
|JNJ||Johnson & Johnson||-0.09%||163.72||0.7%||$1029.28m|
|BMY||Bristol-Myers Squibb Co.||0.87%||58.09||1.0%||$658.95m|
|LLY||Eli Lilly & Co.||0.64%||243.85||1.1%||$610.94m|
|AVIR||Atea Pharmaceuticals, Inc.||-4.20%||13.24||0.3%||$116.76m|
|NVO||Novo Nordisk A/S||-0.09%||104.56||0.1%||$91.61m|
|EDSA||Edesa Biotech, Inc.||-0.97%||8.14||0.0%||$73.37m|
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.